Agents targeting BRAF and MEK demonstrated their efficacy in NSCLC patients harboring class 1 BRAF mutations, and their use has been recently approved by most regulatory agencies [10,11]. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.